Umbilical Cords Provide Immune System Boost for Patients with Lymphoma?

According to new research conducted by students at John Hopkins University, stem cells from newborn umbilical cords and placenta should be utilized, not tossed away as they presently are. The students insist that the stem cells would be better served if they were used to boost the immune systems of patients with leukemia, lymphoma and other blood disorders.

The students -- who are currently pursuing a master’s degree at the university’s Center for Bioengineering Innovation and Design -- make use of the CBx System in their efforts. Although the technology is still in the testing stage, the students have already obtained a provisional patent for the technology and crated the company TheraCord LLC.

“Cord blood, collected from the umbilical cord and placenta after live birth, is the most viable source of stem cells, yet over 90 percent is uncollected and discarded,” the team members wrote for a presentation at the university's recent Biomedical Engineering Design Day. “One of the main reasons valuable cord blood is so frequently discarded is because no adequate collection method exists.”

With this in mind, parents can now save the cord blood when their baby is born, and apply it in a way that can benefit either their family or another.

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap